Current News

Print version | PDF version | Send article | RSS feed

Morphochem enters Research Alliance with Alcon to develop novel ophthalmic compounds

11 Jan 2005 - Morphochem AG announced that it has entered into a research alliance with Alcon Research, Ltd. to develop small molecule drugs against important ophthalmic targets. The alliance combines Morphochem's compound design and synthesis capabilities and its biostructure group expertise with Alcon's applied biology expertise, screening capabilities and development expertise. Morphochem will use its evolutionary design and synthesis capabilities by applying its proprietary software - MolMindŽ, to make focused libraries for certain Alcon targets. It will also work on establishing the biostructure of one of the targets with the goal to identifying compounds from structurally novel compound classes.
 
Under the terms of the agreement, Alcon will retain the rights to any products for ophthalmic and nasal applications and Morphochem will retain certain rights to all other uses of drug candidates discovered during the alliance.
 
Alcon will pay Morphochem research payments, and undisclosed amounts through a series of development milestones and royalties on sales.